Answers are grounded in this paper and cite their sources.
Advanced cutaneous squamous cell carcinoma (aCSCC) presents a significant therapeutic challenge, especially in patients with severe comorbidities that limit treatment options. Traditional treatments such as surgery and radiation may be unfeasible in frail patients, necessitating alternative therapies like immunotherapy. We present the case of a 79-year-old male with a history of recurrent aCSCC, complicated by multiple severe comorbidities, including coronary artery disease, heart failure, chronic kidney disease, and hypothyroidism. After the development of facial nerve palsy and confirmation of metastatic disease, he was treated with cemiplimab, a PD-1 inhibitor, through an Early Access Program. Despite his complex medical status and fluctuating performance status (ECOG 2-3), the patient showed partial reduction in tumor size and improved quality of life, with no significant adverse effects. This case highlights the potential of cemiplimab as an effective therapeutic option for patients with aCSCC who are ineligible for conventional treatments due to comorbidities, offering an alternative approach to managing this challenging condition.
No takes yet. Share an insight, caveat, or question.
Lapeikis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: